Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 6,958 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 6,958 shares of the stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $2,157,536.64. Following the completion of the sale, the chief executive officer directly owned 85,662 shares of the company’s stock, valued at $26,562,072.96. The trade was a 7.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, January 12th, Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22.

Alnylam Pharmaceuticals Stock Up 5.8%

Shares of NASDAQ ALNY traded up $18.21 during trading on Tuesday, hitting $332.61. The stock had a trading volume of 1,516,365 shares, compared to its average volume of 1,632,567. The firm has a fifty day moving average of $372.67 and a two-hundred day moving average of $424.73. The company has a market capitalization of $44.11 billion, a PE ratio of 194.51 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the firm posted ($0.65) earnings per share. The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $243,000. Geneos Wealth Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares during the period. Envestnet Portfolio Solutions Inc. lifted its holdings in Alnylam Pharmaceuticals by 34.3% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 1,164 shares of the biopharmaceutical company’s stock worth $380,000 after purchasing an additional 297 shares in the last quarter. Nordea Investment Management AB boosted its stake in Alnylam Pharmaceuticals by 10.4% in the 2nd quarter. Nordea Investment Management AB now owns 11,295 shares of the biopharmaceutical company’s stock worth $3,640,000 after purchasing an additional 1,060 shares during the period. Finally, Mutual of America Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 16.9% during the 2nd quarter. Mutual of America Capital Management LLC now owns 15,946 shares of the biopharmaceutical company’s stock valued at $5,200,000 after buying an additional 2,302 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ALNY. Truist Financial dropped their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Jefferies Financial Group lowered their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research note on Thursday, October 30th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Piper Sandler restated an “overweight” rating and set a $489.00 price objective (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Finally, HC Wainwright dropped their target price on shares of Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.